A phase II trial of PF1801
Latest Information Update: 08 Jan 2026
At a glance
- Drugs PF 1801 (Primary)
- Indications Dermatomyositis; Duchenne muscular dystrophy; Polymyositis; Sarcopenia
- Focus Therapeutic Use
Most Recent Events
- 08 Jan 2026 New trial record